Luteinizing hormone-releasing hormone (LHRH) in rat prostate: Characterization of LHRH peptide, messenger ribonucleic acid expression, and molecular processing of LHRH in intact and castrated male rats

Nasrin Azad, Shahab Uddin, Nancy La Paglia, Lidia Kirsteins, Nicholas V. Emanuele, Ann M. Lawrence, Mark R. Kelley

Research output: Contribution to journalArticle

22 Scopus citations


Continuous administration of LHRH agonist suppresses the pituitary-gonadal axis, achieving chemical castration. Thus, LHRH agonist has been used as an alternative (to surgical castration) for the treatment of steroid-dependent prostate cancer. However, recent reports have demonstrated that LHRH agonist had a direct inhibiting effect on prostate cancer cell proliferation and that cancerous prostate tissue contained a LHRH-like peptide. In this paper we are reporting for the first time that the normal rat ventral prostate contained immunoactive and bioactive LHRH as well as its precursor molecule, pro-LHRH. Our investigation showed that the LHRH concentration in prostate increased 2 weeks after castration from 1.68 ± 0.09 to 3 ± 0.2 pg/mg tissue (P < 0.001). At the same time, the concentration of pro-LHRH decreased from 149 ± 6.5 to 68 ± 6.8 pg/mg tissue (P < 0.001). Furthermore, intact rat prostate expressed LHRH mRNA, which increased 13-fold 2 weeks after castration. In summary, the prostate of intact Sprague-Dawley rats has the capacity to produce the LHRH precursor and process it to the mature decapeptide, and this production/processing increases significantly after castration.

Original languageEnglish (US)
Pages (from-to)1252-1257
Number of pages6
Issue number3
StatePublished - Sep 1993


ASJC Scopus subject areas

  • Endocrinology

Cite this